Cellular Dynamics (ICEL)

[biocqr]

1Q 2013 sales were $1.75M...that's a 65% seq increase from 1Q...pretty good. Gross margins grew to 66% vs. 64% in 1Q.

also cash position looks healthy to absorb the losses.

Cash and cash equivalents. On June 30, 2013, cash and cash equivalents totaled $33.5 million. On June 28, 2013, the Company borrowed $12.0 million under a credit agreement with Sixth Floor Investors LP and other lenders. In connection with the borrowing, $222,000 of debt issuance costs were incurred. Subsequent to the close of the quarter on July 30, 2013, CDI closed its initial public offering, receiving net proceeds of approximately $41.0 million, leaving a balance of cash and cash equivalents in excess of $74 million.

Decent report IMO.